Surveillance after orchiectomy alone has become popular in the management of clinical stage I nonseminomatous germ cell testicular tumors (CSI NSGCTT). Efforts to identify patients at high risk of disease progression led to a search for risk factors in CSI NSGCTT. The aim of this study was to analyze a 25-year single-center experience with risk-adapted therapeutic approaches—active surveillance (AS) versus adjuvant chemotherapy (ACT).
Patients and Methods
From January 1992 to January 2017, a total of 485 patients with CSI NSGCTT were stratified into the AS group (low-risk patients) and the ACT group (high-risk patients). Differences between relapse rates and overall survival rates in these groups were statistically analyzed.
In the AS group, relapse occurred in 52 (17.3%) of 301 patients with a median follow-up of 7.2 months (range, 2-86 months). Six (2.0%) patients of this group died, with a median follow-up of 34.3 months (range, 11-102 months). In the ACT group, relapse occurred in 2 (1.1%) of 184 patients with a median follow-up of 56.2 months (range, 42-70 months). One (0.54%) patient died at 139.4 months following orchiectomy. The relapse rate for the AS group was 16.7 times higher than that for the ACT group. The groups did not differ in overall survival. The 3-year overall survival of all patients with CSI NSGCTT was 99.1% (95% confidence interval, 97.7%-99.7%). Three of a total of 7 deaths occurred thereafter.
The policy of AS is recommended only in patients with low-risk CSI NSGCTT.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Genitourinary Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.Ann Intern Med. 1977; 87: 293-298
- Orchidectomy alone in testicular stage I nonseminomatous germ cell tumors.Lancet. 1982; 2: 678-680
- Surveillance alone for patients with clinical stage I nonseminomatous germ cell tumors of the testis: preliminary report.J Urol. 1984; 131: 491-493
- Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis.J Clin Oncol. 1984; 2: 267-270
- Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance.J Clin Oncol. 1988; 6: 1597-1603
- Orchiectomy alone for clinical stage nonseminomatous germ cell tumors of the testis (NSGCTT): a minimum follow-up period of 5 years.Tumori. 1994; 80: 362-364
- Surveillance after orchiectomy for patients with clinical stage I nonseminomatous testis tumors.J Clin Oncol. 1992; 10: 564-568
- Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study.J Clin Oncol. 1990; 8: 509-518
- Identifying patients with low risk clinical stage nonseminomatous testicular tumors who should be treated by surveillance.Urology. 1980; 34: 339-343
- Low sperm counts as a prognostic factor of progression in stage I non-seminomatous germ cell testicular tumours.Br J Urol. 1988; 62: 82-84
- The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).Neoplasma. 1996; 43: 195-197
- Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment.Eur Urol. 1998; 33: 562-566
- Nonseminomatous germ cell testicular tumors – clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.Neoplasma. 2007; 54: 437-442
- European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.Eur Urol. 2008; 53: 478-496
- Guidelines on testicular cancer: 2015 update.Eur Urol. 2015; 68: 1054-1068
- Controversies in the management of stage I non-seminomatous germ cell tumors.Curr Urol Rep. 2013; 14: 506-510
- Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group trial.J Clin Oncol. 2003; 21: 1505-1512
- Challenging the EAU 2009 guidelines on testis cancer: the risk-adapted management of stage I nonseminomatous germ cell tumours: surveillance yields equal results with less toxicity.Eur Urol Suppl. 2010; 9: 459-461
- News in adjuvant therapy of non-seminomatous germ cell testicular tumors of stage I.Klin Onkol. 2016; 29: 107-110
- Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy.Ann Oncol. 2010; 21: 1296-1301
- Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.Eur Urol. 2011; 59: 556-562
- Active surveillance is the preferred approach to clinical stage I testicular cancer.J Clin Oncol. 2013; 31: 3490-3493
- Treatment of nonseminoma: Stage I.in: Laguna M.P. Albers P. Bokemeyer C. Richie J.P. Cancer of the testis. Springer Verlag, London2010: 147-166
- Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.J Clin Oncol. 2009; 27: 2122-2128
- One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group.Ann Oncol. 2014; 25: 2167-2172
- Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.J Clin Oncol. 2008; 26: 2966-2972
- High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy.World J Urol. 2009; 27: 455-461
- Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up.Ann Oncol. 2013; 24: vi125-vi132
- Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.Ann Oncol. 2015; 26: 833-838
- Management of stage I testicular germ cell tumors.Nat Rev Urol. 2016; 13: 663-673
Published online: June 01, 2017
Accepted: May 23, 2017
Received in revised form: May 21, 2017
Received: March 25, 2017
© 2017 Elsevier Inc. All rights reserved.